Overview

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101

Status:
Completed

Trial end date:
2006-11-10

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of children with hemophilia A. The study is open to pediatric patients in Canada who completed Baxter Study 060101.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Baxalta now part of Shire
Baxalta US Inc.

Treatments:

Factor VIII